5HT3 Antagonism and Auditory Gating in Schizophrenia

US Department of Veterans Affairs (VA)

Status: Completed

Conditions: Schizophrenia

Treatments: Behavioral: neuropsychological testing; Drug: haloperidol; Drug: ondansetron; Drug: nicotine

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT00018850

MHBS-013-99F

Details and patient eligibility

About

The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Subjects with diagnosed with schizophrenia will be studied.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind